Background & Objective: Pancreatic cancer is one of the most lethal malignancies accounting
for the fourth leading cause of cancer-related deaths in the United States. Among several explored
anticancer agents, Gemcitabine, a nucleoside analogue remained a front line chemotherapeutic agent
for the treatment of pancreatic cancer. However, gemcitabine exerts a low response rate with limited
progression free survival in patients due to cellular resistance of pancreatic tumors to this therapy.
Several chemotherapeutic agents have been explored in combination with gemcitabine against pancreatic
cancer with overall mixed responses and survival rates. Naturally occurring dietary agents possess
promising anticancer properties and have been shown to target various oncogenic signaling pathways
in in-vitro and in-vivo pancreatic cancer models.
Results: Multiple studies using natural compounds have shown increased therapeutic efficacy of gemcitabine
in pancreatic cancer models.
Conclusion: This review is focused on recent updates on cellular, preclinical and clinical studies utilizing
natural anticancer agents with gemcitabine against pancreatic cancer.